# A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Source: https://onco.cc/trials/nct05645692/  
OnCo record `nct05645692` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Atezolizumab and Tiragolumab in bladder & urothelial cancer, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer is a phase 2 interventional study registered as NCT05645692 by Hoffmann-La Roche, with 204 participants enrolled, started 2023-04-13 and due to reach its primary completion in 2026-12-31. Interventions recorded: Atezolizumab, Tobemstomig and Tiragolumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05645692
- Phase: 2
- Setting: A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy
- Sponsor: Hoffmann-La Roche
- Enrolled: 204

## Sources

- ClinicalTrials.gov NCT05645692: https://clinicaltrials.gov/study/NCT05645692

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Tiragolumab](https://onco.cc/drugs/tiragolumab/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct05645692.json